Formoterol or tiotropium bromide do not influence isolated nocturnal hypoxemia in stable COPD Source: Eur Respir J 2005; 26: Suppl. 49, 294s Year: 2005
Cardiopulmonary effects of inhaled ipratropium bromide and its combination with fenoterol in patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 58s Year: 2002
Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD Source: Eur Respir J 2007; 30: Suppl. 51, 356s Year: 2007
Reversibility effects of ipratropium bromide and terbutalin sulphate in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 72s Year: 2001
Ipratropium bromide effects on intraocular pressure in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 287s Year: 2005
Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children Source: Eur Respir J 2004; 24: Suppl. 48, 167s Year: 2004
Airway tone during exercise in healthy subjects: effects of salbutamol and ipratropium bromide Source: Eur Respir J 2003; 22: Suppl. 45, 89s Year: 2003
Effect of patient age on response to nebulised salbutamol or ipratropium bromide Source: Annual Congress 2012 - Going with the flow: assessment and evaluation of airway function and its role in patient management Year: 2012
The combination therapy with inhaled tiotropium bromide and transdermal tulobuterol in COPD improves the peripheral airway function Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
A comparison of bronchodilating response of salbutamol, ipratropium bromide and the combination of ipratropium-salbutamol in patients with stable chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001
Effects of long-acting inhaled β-adrenergic and anticholinergic drugs on respiratory function and arterial blood gases in patients with COPD Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006
Pulmonary function and bronchodilator response to albuterol, ipratropium bromide and association of albuterol and ipratropium bromide in children with cystic fibrosis (CF) Source: Eur Respir J 2003; 22: Suppl. 45, 229s Year: 2003
Effects of tiotropium bromide on bronchial obstruction and exercise tolerance in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006
Acute effect of formoterol, salmeterol, albuterol, oxitropium bromide and placebo on FEV1, inspiratory capacity and dyspnoea in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 380s Year: 2001
Lung function response to budesonide and ipratropium bromide in COPD patients who continue smoking Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002
Influence of tiotropium bromide and formoterol on bronchial hyperresponsiveness in COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Selection of the optimal nebulizer for further clinical development of inhaled nebulized nitrite (AIR001) in pulmonary arterial hypertension patients Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD Source: Eur Respir J 2003; 21: 86-94 Year: 2003
Effect of salbutamol, formoterol and ipratropium bromide on exhaled nitric oxide in asthmatic patients and healthy volunteers Source: Annual Congress 2010 - Asthma: breath biomarkers and asthma control Year: 2010
The acute effect of inhaled salbutamol and ipratropium on microvascular function Source: International Congress 2018 – Basic pharmacology Year: 2018